Total Incidents: According to Rankiteo, Biocon has faced 0 incidents in the past.

Incident Types: As of the current reporting period, Biocon has not encountered any cybersecurity incidents.

Total Financial Loss: The total financial loss from these incidents is estimated to be {total_financial_loss}.

Cybersecurity Posture: The company's overall cybersecurity posture is described as Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients..

Detection and Response: The company detects and responds to cybersecurity incidents through {description_of_detection_and_response_process}.

Common Attack Types: As of now, the company has not encountered any reported incidents involving common cyberattacks.

Identification of Attack Vectors: The company identifies the attack vectors used in incidents through {description_of_identification_process}.

Average Financial Loss: The average financial loss per incident is {average_financial_loss}.

Commonly Compromised Data Types: The types of data most commonly compromised in incidents are {list_of_commonly_compromised_data_types}.

Incident Response Plan: The company's incident response plan is described as {description_of_incident_response_plan}.

Third-Party Assistance: The company involves third-party assistance in incident response through {description_of_third_party_involvement}.

Prevention of Data Exfiltration: The company takes the following measures to prevent data exfiltration: {description_of_prevention_measures}.

Handling of PII Incidents: The company handles incidents involving personally identifiable information (PII) through {description_of_handling_process}.

Ransom Payment Policy: The company's policy on paying ransoms in ransomware incidents is described as {description_of_ransom_payment_policy}.

Data Recovery from Ransomware: The company recovers data encrypted by ransomware through {description_of_data_recovery_process}.

Regulatory Frameworks: The company complies with the following regulatory frameworks regarding cybersecurity: {list_of_regulatory_frameworks}.

Ensuring Regulatory Compliance: The company ensures compliance with regulatory requirements through {description_of_compliance_measures}.

Key Lessons Learned: The key lessons learned from past incidents are {list_of_key_lessons_learned}.

Implemented Recommendations: The company has implemented the following recommendations to improve cybersecurity: {list_of_implemented_recommendations}.

Additional Resources: Stakeholders can find additional resources on cybersecurity best practices at {list_of_additional_resources}.

Communication of Investigation Status: The company communicates the status of incident investigations to stakeholders through {description_of_communication_process}.

Advisories Provided: The company provides the following advisories to stakeholders and customers following an incident: {description_of_advisories_provided}.

Monitoring and Mitigation of Initial Access Brokers: The company monitors and mitigates the activities of initial access brokers through {description_of_monitoring_and_mitigation_measures}.

Post-Incident Analysis Process: The company's process for conducting post-incident analysis is described as {description_of_post_incident_analysis_process}.

Corrective Actions Taken: The company has taken the following corrective actions based on post-incident analysis: {list_of_corrective_actions_taken}.

Ransom Payment History: The company has {paid/not_paid} ransoms in the past.

Last Ransom Demanded: The amount of the last ransom demanded was {last_ransom_amount}.

Last Attacking Group: The attacking group in the last incident was {last_attacking_group}.

Most Recent Incident Detected: The most recent incident detected was on {most_recent_incident_detected_date}.

Most Recent Incident Publicly Disclosed: The most recent incident publicly disclosed was on {most_recent_incident_publicly_disclosed_date}.

Most Recent Incident Resolved: The most recent incident resolved was on {most_recent_incident_resolved_date}.

Highest Financial Loss: The highest financial loss from an incident was {highest_financial_loss}.

Most Significant Data Compromised: The most significant data compromised in an incident was {most_significant_data_compromised}.

Most Significant System Affected: The most significant system affected in an incident was {most_significant_system_affected}.

Third-Party Assistance in Most Recent Incident: The third-party assistance involved in the most recent incident was {third_party_assistance_in_most_recent_incident}.

Containment Measures in Most Recent Incident: The containment measures taken in the most recent incident were {containment_measures_in_most_recent_incident}.

Most Sensitive Data Compromised: The most sensitive data compromised in a breach was {most_sensitive_data_compromised}.

Number of Records Exposed: The number of records exposed in the most significant breach was {number_of_records_exposed}.

Highest Ransom Demanded: The highest ransom demanded in a ransomware incident was {highest_ransom_demanded}.

Highest Ransom Paid: The highest ransom paid in a ransomware incident was {highest_ransom_paid}.

Highest Fine Imposed: The highest fine imposed for a regulatory violation was {highest_fine_imposed}.

Most Significant Legal Action: The most significant legal action taken for a regulatory violation was {most_significant_legal_action}.

Most Significant Lesson Learned: The most significant lesson learned from past incidents was {most_significant_lesson_learned}.

Most Significant Recommendation Implemented: The most significant recommendation implemented to improve cybersecurity was {most_significant_recommendation_implemented}.

Most Recent Source: The most recent source of information about an incident is {most_recent_source}.

Most Recent URL for Additional Resources: The most recent URL for additional resources on cybersecurity best practices is {most_recent_url}.

Current Status of Most Recent Investigation: The current status of the most recent investigation is {current_status_of_most_recent_investigation}.

Most Recent Stakeholder Advisory: The most recent stakeholder advisory issued was {most_recent_stakeholder_advisory}.

Most Recent Customer Advisory: The most recent customer advisory issued was {most_recent_customer_advisory}.

Most Recent Entry Point: The most recent entry point used by an initial access broker was {most_recent_entry_point}.

Most Recent Reconnaissance Period: The most recent reconnaissance period for an incident was {most_recent_reconnaissance_period}.

Most Significant Root Cause: The most significant root cause identified in post-incident analysis was {most_significant_root_cause}.

Most Significant Corrective Action: The most significant corrective action taken based on post-incident analysis was {most_significant_corrective_action}.